Chronic Infection Article 1: EBV, HHV-6, Tick-Borne Disease, and the Infection That Never Ended in ME/CFS
The gland in your neck has been up since you “recovered” from mono years ago. You flare when you are stressed — the sore throat returns, the lymph nodes ache, the fatigue deepens — and you are told it is “past infection.” Your antibody tests show high titres to EBV and HHV-6, but the infectious-disease specialist says that only means you were exposed, not that the virus is active. Something is still talking to your immune system.
Now add the rest of ME/CFS: the PEM, the unrefreshing sleep, the brain fog. About 70% of ME/CFS cases follow an acute infection — EBV mononucleosis, HHV-6 roseola, tick-borne Borrelia, enterovirus, SARS-CoV-2 — and the question that has haunted the field for decades is whether the pathogen is still there, still driving the disease, or whether it lit a fire and walked away. The strongest prospective precedent is the Dubbo cohort, where a substantial share of people with EBV, Ross River virus, or Q-fever infections developed a post-infective fatigue syndrome (Hickie et al. 2006).
This article is the conceptual overview. What EBV, HHV-6, and tick-borne pathogens actually do in ME/CFS, the abortive-lytic-replication model that explains why antiviral antibodies are high but viral load is undetectable, the EBV→mast cell→MMP-9 pathway, the poly-herpesvirus co-reactivation pattern, and the difference between active infection on its own and chronic immune stimulation on top of ME/CFS. The treatments — antivirals, immunomodulators, and why the evidence is thinner than the mechanisms — are covered in the companion treatment article.
1 First, a plain warning
This is an explanation, not self-medication advice, and I am not a doctor. Antiviral medications (valacyclovir, valganciclovir) require a prescriber and renal monitoring. Tick-borne infections require specialist evaluation — untreated Lyme can progress to neurological and cardiac complications. If you have a new bull’s-eye rash, facial palsy, or joint swelling after a tick bite, seek urgent medical attention.
2 The short version, if you only read one part
- A large share of ME/CFS cases follow an acute infection (commonly cited around 70%, though the exact proportion is debated and retrospective), and the Big Four are EBV/mononucleosis, HHV-6 (roseola → neurotropic, integrates into chromosomes), tick-borne Borrelia (Lyme), and SARS-CoV-2 — each of which is documented to precede a subset of ME/CFS and post-infectious fatigue cases.
- The central puzzle is abortive lytic replication (ALR). The virus enters the lytic cycle — expressing immunostimulatory proteins — but stops before producing virions. There is no measurable viral load in blood, but the viral proteins (dUTPases, immediate-early genes) are still being made, and the immune system still sees them. This explains why antibody titres are high but PCR is negative (Cox et al. 2022).
- EBV directly activates mast cells. Recombinant EBV protein added to human mast cells increased MMP-9 release nearly sixfold (2,464 vs 433 pg/ml) — and MMP-9 degrades the blood-brain barrier, allowing peripheral inflammatory mediators to access the brain (Chinnappan et al. 2026).
- Poly-herpesvirus co-reactivation is the rule, not the exception. 72.5% of ME/CFS patients had elevated antibodies to multiple herpesvirus dUTPases vs 31% of controls. EBV, HHV-6, CMV, and VZV can reactivate together — the immune system is fighting a multi-front viral war with depleted resources (Palomo et al. 2026).
- Chronic infection is the most hypothesis-heavy topic in the Septad. It is mechanistically central but harder to treat plainly — antivirals that block DNA replication in fully lytic virus may be ineffective against ALR, and the evidence for them in ME/CFS is weak and unreplicated.
3 The EBV connection: mechanism, not serology
Epstein-Barr virus infects >90% of the world’s population. In most people, it establishes latency in B-cells and remains quiescent for life, suppressed by T-cell surveillance. In ME/CFS, several lines of evidence point to EBV reactivation — but “reactivation” does not mean the same thing as acute mononucleosis.
3.1 Abortive lytic replication (ALR)
In full lytic replication, the virus expresses immediate-early genes (BZLF1, BRLF1), then early genes (including BLLF3, the dUTPase), replicates its DNA, assembles virions, and lyses the cell. ALR stops after the early-gene stage — the viral proteins are made, but no infectious virus is produced. The cell is not killed, but it is expressing viral antigens that the immune system must continuously suppress.
Why this matters for ME/CFS: ALR explains the immunological signature — high antibodies to lytic antigens (EA-D, VCA, dUTPase), but undetectable or low viral DNA in blood. The virus is not “replicating” in the conventional sense, but it is actively producing proteins that drive immune activation, inflammation, and — critically — mast-cell degranulation (Cox et al. 2022).
3.2 The dUTPase problem
dUTPase is a conserved herpesvirus enzyme that converts dUTP to dUMP, preventing uracil misincorporation into viral DNA. It is also a potent pathogen-associated molecular pattern (PAMP) — the innate immune system recognises dUTPase through TLR2 and triggers NF-κB-driven cytokine production. The dUTPases of EBV (BLLF3), HHV-6 (U45), VZV (ORF8), and CMV are structurally similar enough that one reactivating virus can produce a dUTPase that cross-stimulates the immune response to another — a mechanistic basis for poly-herpesvirus co-reactivation (Cox et al. 2022).
The EBV dUTPase also activates NF-κB in mast cells, which drives MMP-9 expression. This is the bridge between the viral-reactivation story and the connective-tissue degradation story covered in the hypermobility articles: a reactivating herpesvirus produces a protein (dUTPase) that tells mast cells to release an enzyme (MMP-9) that degrades collagen and opens the blood-brain barrier. The virus is not in the brain. But its downstream products get there.
3.3 EBV→mast cell→MMP-9: the pathway in numbers
Chinnappan et al. (2026) tested the direct effect of recombinant EBV protein on human mast cells in culture: - MMP-9 release: 2,464 pg/ml (EBV) vs 433 pg/ml (unstimulated), p<0.001, n=3 - For comparison, LPS (a bacterial PAMP) produced 1,422 pg/ml — EBV was 1.7× more potent than LPS at driving MMP-9 - The same study found elevated serum IL-11 in ME/CFS patients — a cytokine that amplifies MMP-9 expression from microglia, creating a second MMP-9 amplification loop in the brain
Honesty caveats, because they matter. The study used cord-blood mast cells (not patient mast cells), n=3 (12-week culture requirement limits replication), serum rather than plasma (MMP-9 is 3–4× higher in serum due to platelet degranulation during clotting), and the ME/CFS and control groups were not age-matched. The finding has not been independently replicated. The effect direction — EBV protein activates mast cells to release MMP-9 — is mechanistically important and biologically plausible, but the magnitude and specificity are provisional (Chinnappan et al. 2026).
4 HHV-6: the neurotropic integrator
Human herpesvirus 6 (HHV-6) infects nearly all children by age 2 (causing roseola) and establishes latency in T-cells, monocytes, and — critically — in the central nervous system. HHV-6 is the only human herpesvirus that can integrate into the host chromosome (ciHHV-6), creating a permanent genetic reservoir that standard antivirals cannot clear.
In ME/CFS, several findings point to HHV-6 involvement:
- miR-aU14 meets mitochondria. HHV-6 encodes a microRNA, miR-aU14, that inhibits the host’s miR-30 family. miR-30 normally suppresses p53 and DRP1 — removing that inhibition activates p53-dependent DRP1 translocation to mitochondria, causing mitochondrial fragmentation. The virus does not infect mitochondria directly. It sends a microRNA that tells the cell to break its own mitochondria (Schreiner et al. 2020).
- Post-mortem neuroinvasion. HHV-6 miR-aU14 was found in the choroid plexus, hippocampus, amygdala, and dorsal root ganglia of ME/CFS patients at autopsy — and was absent in 24 controls. The sample was n=3, so this is a finding, not a settled fact. But it places a viral nucleic acid in the exact brain regions implicated in ME/CFS cognitive, autonomic, and sensory symptoms.
- Prevalence. Latent or persistent HHV-6 has been reported in around 47% of ME/CFS patients vs roughly 10% of controls in some studies (single-study figures; ranges vary by assay and definition).
5 Tick-borne disease: Lyme, Bartonella, Babesia
Lyme disease (Borrelia burgdorferi) causes acute infection treated with 2–4 weeks of antibiotics. In 10–20% of cases, symptoms persist for months to years — post-treatment Lyme disease syndrome (PTLDS). PTLDS is reported to overlap heavily with ME/CFS on the core symptom set (fatigue, cognitive dysfunction, musculoskeletal pain, sleep disturbance), making the two conditions nearly clinically indistinguishable in the post-infectious phase.
The mechanism debate mirrors the EBV debate: is there persistent Borrelia (antibiotic-refractory reservoirs, biofilm-protected spirochetes) or is PTLDS a post-infectious immune dysregulation that outlasts the pathogen? The evidence for persistent infection — culture, PCR, xenodiagnosis — exists but is inconsistent and technically challenging. The evidence for post-infectious immune dysregulation — elevated cytokines, T-cell exhaustion, autoantibody generation — is robust and mirrors ME/CFS (Nawrocki et al. 2025).
Bartonella and Babesia are tick-borne co-infections that are less studied than Lyme. Bartonella DNA has been detected in ~26% and Babesia in ~24% of ME/CFS cohorts — but these studies lacked healthy controls, so the baseline community prevalence (which is not zero) is unknown. The honest position: tick-borne co-infections are plausible contributors in the exposed individual; the evidence for them as a general ME/CFS mechanism is weak.
6 Poly-herpesvirus co-reactivation
The immune system does not fight one herpesvirus at a time. The 72.5% poly-herpesvirus seroreactivity rate (vs 31% in controls) suggests that when immune surveillance weakens — and T-cell exhaustion, NK dysfunction, and CD8+ senescence are all documented in ME/CFS — multiple latent herpesviruses reactivate simultaneously (Palomo et al. 2026).
This creates a treatment problem. Valacyclovir inhibits EBV DNA polymerase (lytic replication) but has no effect on HHV-6. Valganciclovir covers HHV-6 and CMV but is more toxic. No single antiviral covers all four (EBV, HHV-6, CMV, VZV) without additive toxicity. And none of them block ALR, because the early viral proteins are produced before the DNA-polymerase step that the drugs target.
7 Chronic infection by itself vs ME/CFS with chronic infection
Active chronic infection on its own (no ME/CFS). Active EBV replication (PCR-positive, detectable viral load), active Lyme (culture or PCR-confirmed), active HHV-6 (viremia in transplant patients) — these are infectious diseases treated with antivirals or antibiotics. If the pathogen is identified and a drug exists that targets it, treatment is straightforward: give the drug, monitor the pathogen, confirm clearance.
ME/CFS with chronic immune stimulation (the situation this series is about). When the infection history is in the past and the current problem is ALR, immune dysregulation, or post-infectious autoimmunity, the treatment logic changes:
- Antivirals that work against lytic replication may not work against ALR. The viral proteins driving the immune response are produced before the drug’s target step. A negative antiviral trial does not prove the virus is irrelevant — it proves the drug, at that dose, did not interrupt the specific replication stage that is active.
- Eradication may be impossible. Integrated HHV-6 cannot be removed. Latent EBV in memory B-cells is lifelong. The treatment goal shifts from “clear the pathogen” to “suppress the immune activation the pathogen is causing.”
- The host immune defect may be the rate-limiting factor, not the viral load. If T-cells are exhausted and NK cells are dysfunctional, giving an antiviral without addressing the immune defect is like giving a firefighter a smaller hose while the water pressure is dropping. The fire is not the pathogen; the fire is the immune response to the pathogen, and the response is failing because the immune system is depleted.
8 The bottom line
Chronic infection is the most mechanistically central and therapeutically frustrating of the Septad conditions. The evidence that herpesviruses and tick-borne pathogens are involved in ME/CFS is strong — abortive lytic replication, poly-herpesvirus co-reactivation, EBV→mast cell→MMP-9, and HHV-6 mitochondrial fragmentation are not fringe hypotheses. But the evidence that targeting them with current antivirals improves ME/CFS is weak and unreplicated — and the distinction between ALR (which antivirals do not block) and lytic replication (which they do) explains why (Loth 2026).
The treatment companion article covers the antivirals (valacyclovir, valganciclovir, famciclovir), the immunomodulators (cimetidine), the mast-cell stabilisers that intercept the EBV→MMP-9 pathway downstream of the virus, and the honest “what if the antivirals don’t work” discussion.
Next in this mini-series: the antivirals, the evidence, and what a negative trial does and does not tell you [see the companion article].
For the comprehensive, fully-cited picture of how chronic infection is weighed among the many candidate mechanisms in ME/CFS, see (Loth 2026).